title: Bucillamine-induced pemphigus vulgaris in a patient with rheumatoid arthritis and polymyositis overlap syndrome.
abstract: Bucillamine is a disease modifying anti-rheumatic drug, structurally similar to D-penicillamine. Although D-penicillamine-induced pemphigus has been not infrequently demonstrated, pemphigus associated with bucillamine was rarely reported. We describe a patient complicating pemphigus vulgaris after bucillamine treatment in rheumatoid arthritis (RA) and polymyositis (PM) overlap syndrome. PM and RA overlap syndrome was diagnosed three years ago and bucillamine was administrated for 20 months. Skin lesions including erythematous flaccid blisters on her chest, axillae, and back were occurred and were compatible with pemphigus vulgaris by typical pathology. Withdrawal from bucillamine and prednisolone treatment made rapid improvement of pemphigus lesions.
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Diseases, College of Medicine, Hanyang University, Seoul, Korea.
authors.forename: Jin-Wuk
authors.initials: JW
authors.lastname: Hur
authors.forename: Chang-Woo
authors.initials: CW
authors.lastname: Lee
authors.forename: Dae-Hyun
authors.initials: DH
authors.lastname: Yoo
mesh_terms: D000975:Antioxidants / Q000009:adverse effects*; D001168:Arthritis; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy*; D001706:Biopsy; D003545:Cysteine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010392:Pemphigus / Q000139:chemically induced* / Q000473:pathology*; D017285:Polymyositis / Q000150:complications* / Q000188:drug therapy*; D012867:Skin / Q000473:pathology; D013577:Syndrome
chemical_list: D000975:Antioxidants; D003545:Cysteine; C026535:bucillamine